2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…2022 American Transplant Congress
HLA DSA May Not Be Detected in Many Solid Organ Recipients
1Keck School of Medicine, Los Angeles, CA, 2Children's Hospital Los Angeles, Los Angeles, CA
*Purpose: Clinically significant HLA antibodies may not be detected if their unique HLA epitopes are not represented in the single antigen reagents that are routinely…2022 American Transplant Congress
Local Intragraft Humoral Immune Response in Chronic Lung Allograft Dysfunction
*Purpose: Donor HLA-specific antibody (DSA) and antibody against self-antigens (self-antigen antibody) can cause injury and lead to chronic lung allograft dysfunction (CLAD) after lung transplantation…2022 American Transplant Congress
Which is More Important for Predicting De Novo DSA Production, B Cell Epitope (EPLET) or T Cell Epitope (PIRCHE) Analysis ?
*Purpose: De novo donor-specific antibodies (dnDSA) can cause chronic ABMR, resulting in poor prognosis. Recently, mismatch at B cell epitope level, i.e. EPLET mismatch, has…2022 American Transplant Congress
Early Clinical Complications Following HLA-Incompatible Living Donor Kidney Transplantation
1Johns Hopkins University, Baltimore, MD, 2University of Wisconsin-Madison, Madison, WI
*Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…2022 American Transplant Congress
Three-Way Comparison of Central DSA, %dd-cf DNA, and Molecular Biopsy Findings in the Trifecta Study
*Purpose: Trifecta (ClinicalTrials.gov #NCT04239703) is a prospective, IRB-approved, consented study of the relationships among three central tests in kidney transplant indication biopsies: molecular biopsy diagnoses…2022 American Transplant Congress
Clazakizumab® (anti-il-6) Desensitization in Highly-HLA Sensitized Patients Awaiting Kidney Transplant (nct03380962): Long-Term Follow Up
*Purpose: IL-6 is a cytokine critical for B-cell activation and IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6.…2022 American Transplant Congress
Outcomes of a Standardized Antibody-Mediated Rejection (AMR) Treatment Protocol in Heart Transplant Recipients (HTR)
Baylor University Medical Center, Dallas, TX
*Purpose: AMR in HTR portends poor clinical outcomes. Reported mortality range between 20-50%, with higher rates reported for late AMR occurring at least 1 year…2022 American Transplant Congress
Dynamic Changes of Serum Soluble B Cell Activating Factor in Kidney Transplant with De Novo Donor Specific Antibody
*Purpose: De novo donor specific antibody (dnDSA) plays a crucial role in the development of antibody mediated rejection (ABMR) and is correlated to the worse…2022 American Transplant Congress
Simultaneous Liver/ Kidney Transplant Reduces Both Donor Specific and Non-Donor Specific HLA Antibodies
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Kidney allografts can be transplanted across strong donor specific antibody (DSA) barriers in simultaneous liver/kidney transplant (SLK) recipients. It is suggested that preformed DSAs…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 47
- Next Page »